BENZAMYCIN 5 %
BENZOYL PEROXIDE : 5 % ERYTHROMYCIN : 3 % · DIN 02225271 · BAUSCH HEALTH, CANADA INC.
Health Canada status: MARKETED
What is BENZAMYCIN?
BENZAMYCIN 5 % contains BENZOYL PEROXIDE : 5 % ERYTHROMYCIN : 3 %. It is listed in the Health Canada Drug Product Database under DIN 02225271, held by BAUSCH HEALTH, CANADA INC., supplied as GEL for TOPICAL administration. Health Canada currently lists it as marketed, status dated 01-Oct-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02225271 |
|---|---|
| Brand name | BENZAMYCIN |
| Generic / active ingredient | BENZOYL PEROXIDE : 5 % ERYTHROMYCIN : 3 % |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 5 % |
| Dosage form | GEL |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D10AF52 ERYTHROMYCIN, COMBINATIONS |
| AHFS class | 84:28.00 ; 84:04.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Oct-2020 |
| Original market date | 1996-11-05 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code D10AF52 ERYTHROMYCIN, COMBINATIONS. 1 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ERYSOL | 75 % | GEL | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02034506 |
| SANS-ACNE SOLUTION | 44 % | SOLUTION | GALDERMA CANADA INC | CANCELLED POST MARKET | DIN 01902628 |
| STATICIN LOT | 55 % | LOTION | WESTWOOD-SQUIBB, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 01910086 |
| STIEVAMYCIN FORTE | 4 % | GEL | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 01945262 |
| STIEVAMYCIN MILD | 4 % | GEL | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02015994 |
| STIEVAMYCIN REGULAR | 4 % | GEL | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 01905112 |
| T-STAT LOT | 71.2 % | LOTION | WESTWOOD-SQUIBB, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 02047802 |
| T-STAT PAD-LOT | 2 % | PAD ; LOTION | WESTWOOD-SQUIBB, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 02047799 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.